Drugs / BD113vVLP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06465537 | Jun 2024 → Dec 2025 | open-angle glaucoma | Shanghai BDgene Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD113vVLP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465537 ↗ |
| Action | Inhibit | “It works to knock out or knock down the mutated MYOC gene.” NCT06465537 ↗ |
| Route | Other | “The BD113vVLP is administrated by intracamerally injecton” NCT06465537 ↗ |
| Target | MYOC | “It works to knock out or knock down the mutated MYOC gene.” NCT06465537 ↗ |